Real Time Continuous Glucose Monitoring System in T2DM With Pregnacy

NCT05947916 · tracked via the Priya Life Science China tracker

Sponsor

Peking University Third Hospital

Phase

Not applicable

Started

2024-01-30

Last updated

2026-07-02

Condition(s) studied

Type2diabetesPregnancy RelatedContinuous Glucose MonitoringTime in RangePregnancy Outcome

Investigational drug(s) / intervention(s)

Real-time Continuous Glucose Monitoring System

Real-time Continuous Glucose Monitoring System: The intervention group wore real-time CGM (120 cases) to monitor blood glucose, and was required to use real-time-CGM more than 50% of the time every 4 weeks, the more the better.

Study summary

The prevalence of type 2 diabetes mellitus (T2DM) in women of childbearing age is increasing rapidly, and low glucose compliance leads to an increased risk of adverse pregnancy outcomes for mothers and infants during pregnancy in women with T2DM. Real-time continuous glucose monitoring (CGM) is an important tool for glucose monitoring and patient education, as it can continuously record blood glucose throughout the day and provide real-time feedback on high and low blood glucose levels. This is a multicenter, open-label, randomized controlled clinical study to investigate the efficacy, safety, and maternal and infant pregnancy outcomes of using real-time CGM monitoring compared with conventional self-monitoring of blood glucose (SMBG) on the basis of multidisciplinary management in pregnant women with T2DM. One hundred and twenty pregnant women with T2DM in early pregnancy who were enrolled in intensive insulin therapy were randomly divided into the real-time CGM group and the conventional SMBG group. The real-time CGM intervention group wore real-time CGM for more than 50% of the pregnancy in addition to regular SMBG; the control group only performed regular SMBG. Both groups wore Medtronic iPro 2 for 3 days in early, mid and late pregnancy, and the time in the target range of blood glucose (TIR) was recorded in a blinded manner. Primary outcome: differences in TIR between the two groups of pregnant women in early, mid, and late pregnancy. Secondary outcomes included differences in glycated hemoglobin, hypoglycemia, insulin dose before delivery, pregnancy weight gain, and maternal and infant pregnancy outcomes.

Eligibility

Sex

FEMALE

Min age

18 Years

Max age

40 Years

Healthy volunteers

Inclusion Criteria: * A clear history of type 2 diabetes, or a history of type 2 diabetes diagnosed in early pregnancy * Singleton gestation at 4-26 weeks, with substandard glycemic control (i.e., fasting glucose \> 5.3 mmol/L, and or 1 hour postprandial glucose \> 7.8 mmol/L, and or 2 hours postprandial glucose \> 6.7 mmol/L) after lifestyle intervention ± basal insulin therapy, as assessed by the endocrinology department. Patients who need insulin regimen with basal plus meal or insulin pump regimen. * Patients are willing and committed to establish and follow up in the obstetrics and gynecology departments of Peking University Third Hospital, Haidian District Hospital and Yanqing District Hospital during pregnancy, and are willing to provide information on obstetric examination and perinatal medical records if they are transferred to the hospital for special reasons for follow-up or delivery. * Voluntarily participate in the study, examine and follow up according to this project and sign informed consent. * Able to pass the screening period Adherence evaluation Exclusion Criteria: * Patients with type 1 diabetes, specific type of diabetes or gestational diabetes * Pregnancy with severe comorbidities or diabetic complications for which obstetrics does not recommend continuation of pregnancy, including but not limited to the following: proliferative retinopathy, chronic kidney disease (eGFR less than 60 mL/min/1.73± massive proteinuria), known coronary and cerebrovascular disease, autoimmune system disease and receiving exogenous glucocorticoids or immunosuppressive therapy. * Patients who have been hospitalized for psychiatric treatment within 6 months prior to enrollment or are still on psychiatric medications. * Patients who have received other interventional studies.

Primary outcome measure(s)

The difference of Time in Range (TIR) — 24-28 weeks (second trimester), 34-38 weeks (2 weeks before delivery)
The iPro2 device was used to calculate TIR(the control range of blood glucose during pregnancy was 3.5-7.8mmol/L), and the average value of TIR obtained from two measurements was used as the main outcome index.

Trial sites (1)

Facility	City	Region	Status
Peking University Third Hospital	Beijing	Beijing Municipality	Recruiting

More Peking University Third Hospital trials in China

Exploring the Value of 18F-AlF-FAPI PET/CT in Assessing the Activity of Thyroid Eye Disease Recruiting

Treatment of Oral Lichen Planus With Paeoniflorin and Photodynamic Therapy Recruiting

Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases Recruiting

A Prospective Cohort Study on the Effect of Spinal Spinal Cord Injury on Sexual Function in Male Patients Active, not recruiting

Efficacy and Safety of TTM in Adults With ECPR. Active, not recruiting

Other trials for the same condition

The Clinical Features and Pregnancy Outcomes of CTD Patients Recruiting

Evaluating an Insulin Pump for Time in Range (TIR) in Patients with Type 1 Diabetes Starting soon

Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency Starting soon

GDM and Its Consequences in Mothers and Offsprings Recruiting

Treatment and Clinical Outcomes Among SLE Patients in Pregnancy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05947916 on ClinicalTrials.gov ↗ ← All trials in China